Actively Recruiting
A Study of TRK-950 in Patients With Advanced Solid Tumors
Led by Toray Industries, Inc · Updated on 2026-04-13
49
Participants Needed
10
Research Sites
282 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Part 1 • To determine the safety and tolerability of TRK-950 in patients with advanced solid tumors Part 2 • To determine the safety and tolerability of TRK-950 in combination with nivolumab(NIVO) in patients with advanced solid tumors eligible for NIVO therapy Part 3 • To determine the efficacy of TRK-950 in patients with advanced/recurrent unresectable melanoma, who received prior chemotherapy with dacarbazine(DTIC) and for whom no standard therapy exists
CONDITIONS
Official Title
A Study of TRK-950 in Patients With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 years or older at the time of consent
- Part 1: Patients with locally advanced or metastatic solid tumors refractory or intolerant to standard therapies or with no standard therapy available
- Part 2: Patients with locally advanced or metastatic solid tumors eligible for nivolumab 240 mg administered every 2 weeks
- Part 3: Patients with locally advanced unresectable or metastatic melanoma (excluding uveal melanoma) who received prior chemotherapy with dacarbazine and have no standard therapy
- Patients with life expectancy of at least 3 months after starting study drug
- Patients able to provide written informed consent in person
- Negative pregnancy test before enrollment for females of childbearing potential
You will not qualify if you...
- Patients with active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy
- Pregnant or breastfeeding women, including those possibly pregnant
- Patients unwilling or unable to comply with study procedures
- Patients positive for HIV antibody
- Patients positive for hepatitis B surface antigen (HBsAg)
- Patients positive for hepatitis C virus RNA
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 10 locations
1
Nagoya City University Hospital
Nagoya, Aichi-ken, Japan, 467-8602
Actively Recruiting
2
National Hospital Organization Kyushu Cancer Center
Fukuoka, Fukuoka, Japan, 811-1395
Actively Recruiting
3
Sapporo Medical University Hospital
Sapporo, Hokkaido, Japan, 060-8543
Actively Recruiting
4
Kumamoto University Hospital
Kumamoto, Kumamoto, Japan, 860-8556
Actively Recruiting
5
Shinshu University Hospital
Matsumoto, Nagano, Japan, 390-8621
Actively Recruiting
6
Niigata Cancer Center Hospital
Niigata, Niigata, Japan, 951-8566
Actively Recruiting
7
Saitama Medical University International Medical Center
Hidaka, Saitama, Japan, 350-1298
Actively Recruiting
8
Shizuoka Cancer Center
Nagaizumi-chō, Shizuoka, Japan, 411-8777
Actively Recruiting
9
National Cancer Center Hospital
Chuo Ku, Tokyo, Japan, 104-0045
Actively Recruiting
10
Keio University Hospital
Shinjuku-Ku, Tokyo, Japan, 160-8582
Actively Recruiting
Research Team
T
Toray Contact for Clinical Trial Information
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here